Scholarlink

Background <p>Myelodysplastic syndromes (MDS) represent clonal hematopoietic stem cell disorders with inherent propensity for leukemic transformation. Emerging evidence implicates dysregulated Endoplasmic-Reticulum stress (ER-stress) in sustaining malignant clones through adaptive suppression of pro-apoptotic PERK/CHOP signaling. Celastrol serves as a natural compound with documented ER-stress modulating activity in solid tumors. However, the beneficial effect and molecular mechanisms of celastrol on MDS are unknown.</p> Objective <p>This investigation aims to determine whether celastrol inhibits MDS tumor cell proliferation, and molecular mechanisms of celastrol on MDS involved in the terminal pro-apoptotic ER-stress branches PERK/CHOP axis.</p> Results <p>Celastrol demonstrated cytotoxic effects against MDS cell lines (IC50 1.09 µM-2.02 µM) and primary patient-derived bone marrow mononuclear cells (<i>n</i> = 3, mean apoptosis rate: 42.6%). Flow cytometry results showed that celastrol can induced MDS-L and SKM-1 cell apoptosis. And celastrol treatment can elevate apoptotic protein expression, including cleaved PAPR1, rH2AX and cleaved caspase 3. Celastrol can induce ROS production, and the NAC pretreatment can eliminate the apoptosis-induced effect of celastrol. Our Bulk RNA-seq result of SKM-1 cell and the bone marrow sequencing results of patients with high-risk MDS (GSE19429) suggested that celastrol can activate the terminal pro-apoptotic ER-stress branches PERK/CHOP axis. In consistent, electron microscope screen found celastrol can induce ER Swelling and thickening in a ROS-dependent manner. In vitro experiments, celastrol can increase the eIF2α-ATF4-CHOP protein expression in a ROS-dependent manner. Molecular docking (ΔG -10.9&#xa0;kcal/mol) and CETSA suggested celastrol might bind to BIP protein. In vivo, celastrol monotherapy can reduce tumor burden in xenograft models. Moreover, in MDS-L cell, celastrol can synergistically enhance the effect of venetoclax, as a BCL2 inhibitor inducing tumor cell apoptosis.</p> Conclusion <p>These results indicate that celastrol induces apoptosis in MDS cells and can activate the pro-apoptotic terminal ER-stress response in a ROS-dependent manner. Together, our findings suggest that ER stress activation plays a role in celastrol‑induced apoptosis in MDS cells, supporting further investigation of celastrol as a candidate for MDS therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Celastrol induces apoptosis of myelodysplastic syndrome cells through a ROS-dependent pro-apoptotic endoplasmic-reticulum stress pathway

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月3日

查看全文
  • Fuxiang Zheng,
  • Wenjun Shao,
  • Li Liu,
  • Chaoying Yang,
  • Dingyu Hu,
  • Xiaoling Su,
  • Xuan Li,
  • Pengfei Cao,
  • Jing Liu,
  • Yunlong Xu,
  • Long Liang,
  • Jun He,
  • Ji Zhang

摘要

Background

Myelodysplastic syndromes (MDS) represent clonal hematopoietic stem cell disorders with inherent propensity for leukemic transformation. Emerging evidence implicates dysregulated Endoplasmic-Reticulum stress (ER-stress) in sustaining malignant clones through adaptive suppression of pro-apoptotic PERK/CHOP signaling. Celastrol serves as a natural compound with documented ER-stress modulating activity in solid tumors. However, the beneficial effect and molecular mechanisms of celastrol on MDS are unknown.

Objective

This investigation aims to determine whether celastrol inhibits MDS tumor cell proliferation, and molecular mechanisms of celastrol on MDS involved in the terminal pro-apoptotic ER-stress branches PERK/CHOP axis.

Results

Celastrol demonstrated cytotoxic effects against MDS cell lines (IC50 1.09 µM-2.02 µM) and primary patient-derived bone marrow mononuclear cells (n = 3, mean apoptosis rate: 42.6%). Flow cytometry results showed that celastrol can induced MDS-L and SKM-1 cell apoptosis. And celastrol treatment can elevate apoptotic protein expression, including cleaved PAPR1, rH2AX and cleaved caspase 3. Celastrol can induce ROS production, and the NAC pretreatment can eliminate the apoptosis-induced effect of celastrol. Our Bulk RNA-seq result of SKM-1 cell and the bone marrow sequencing results of patients with high-risk MDS (GSE19429) suggested that celastrol can activate the terminal pro-apoptotic ER-stress branches PERK/CHOP axis. In consistent, electron microscope screen found celastrol can induce ER Swelling and thickening in a ROS-dependent manner. In vitro experiments, celastrol can increase the eIF2α-ATF4-CHOP protein expression in a ROS-dependent manner. Molecular docking (ΔG -10.9 kcal/mol) and CETSA suggested celastrol might bind to BIP protein. In vivo, celastrol monotherapy can reduce tumor burden in xenograft models. Moreover, in MDS-L cell, celastrol can synergistically enhance the effect of venetoclax, as a BCL2 inhibitor inducing tumor cell apoptosis.

Conclusion

These results indicate that celastrol induces apoptosis in MDS cells and can activate the pro-apoptotic terminal ER-stress response in a ROS-dependent manner. Together, our findings suggest that ER stress activation plays a role in celastrol‑induced apoptosis in MDS cells, supporting further investigation of celastrol as a candidate for MDS therapy.